Panthera begins Covid-19 trials

Preston-based clinical trials specialist Panthera Biopartners has begun work evaluating the long-term effects of AstraZeneca's Covid-19 antibody combination.

The firm has begun dosing volunteers in the Phase III PROVENT trial which will evaluate AstraZeneca’s long-acting antibody combination, AZD7442, for the potential prevention of Covid-19.

The antibody combination differs from a vaccine as it provides antibodies, rather than prompting the body's immune system to make them. The treatment is aimed at helping those people with a compromised immune system, who cannot be vaccinated, vaccine hesitant and those who are unlikely to respond to a vaccination.

The double-blind, placebo-controlled trials will take place at its clinical trial sites in Preston, North Manchester and North London. They will feature adult volunteers who have no history of Covid-19 and have an increased risk of infection, including those over 60, a BMI of over 30, a chronic medical condition, taking immunosuppressive medications or those more likely to be exposed, such as NHS workers, or those living in shared accommodation, such as students or the armed services.

The three sites have put in place strict protocols in place to minimise the risk to both volunteers and staff. This enables the company to continue running clinical trials throughout the pandemic.

Stuart Young, CEO of Panthera, said: "We are delighted that we have been chosen to enroll volunteers in this critical study. We have taken great care in making sure our sites are as safe as possible for both volunteers and staff so that clinical trials can continue.

"This is vital in ensuring that there are new medications available to prevent and treat, not only Covid-19, but the many other conditions which afflict so many people."

• For further Lancashire business news, advice and analysis subscribe to Lancashire Business View or join the LBV Hub from just £2.50 per month. Click here to subscribe now.